Last reviewed · How we verify
nebulized epinephrine and nebulized albuterol
Nebulized epinephrine and albuterol work synergistically as bronchodilators and decongestants to rapidly open airways and reduce airway inflammation and edema.
Nebulized epinephrine and albuterol work synergistically as bronchodilators and decongestants to rapidly open airways and reduce airway inflammation and edema. Used for Croup (laryngotracheobronchitis), Acute airway obstruction, Bronchospasm.
At a glance
| Generic name | nebulized epinephrine and nebulized albuterol |
|---|---|
| Sponsor | Rambam Health Care Campus |
| Drug class | Adrenergic agonist combination |
| Target | Alpha-adrenergic receptors, Beta-2 adrenergic receptors |
| Modality | Small molecule |
| Therapeutic area | Pulmonology / Respiratory |
| Phase | FDA-approved |
Mechanism of action
Epinephrine is a non-selective adrenergic agonist that stimulates alpha and beta receptors, causing vasoconstriction and bronchodilation to reduce airway edema and mucus production. Albuterol is a selective beta-2 adrenergic agonist that directly relaxes bronchial smooth muscle. Together, this combination provides rapid relief of airway obstruction through complementary mechanisms of action.
Approved indications
- Croup (laryngotracheobronchitis)
- Acute airway obstruction
- Bronchospasm
Common side effects
- Tachycardia
- Tremor
- Nervousness or anxiety
- Headache
- Palpitations
Key clinical trials
- Randomized Controlled Trial Comparing Standard Versus Positive Pressure Nebulization in Infants With Bronchiolitis to Reduce Hospital Admissions (NA)
- The Effect of Nebulized Epinephrine in Asthma Exacerbation in Pediatric Age Group With the Standard Treatment Compared to Standard Treatment Using Improvement PRAM Score as a Primary Outcome (PHASE4)
- NiPPV in the Treatment of Acute Asthma Exacerbations (NA)
- Acoustic Assessment of Nebulized Epinephrine Versus Albuterol for RSV Bronchiolitis- a Double Blind Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: